observed that 70% of patients with early-stage anti-NMDAR encephalitis had greater CXCL13 levels than healthy controls, implying that CXCL13 could be a potential biomarker of treatment responsiveness in these patients (33). This evidence concerns the gene CXCL13 and viral encephalitis.